about
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.Interleukin-11 induces proliferation of human T-cells and its activity is associated with downregulation of p27(kip1)Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphomaTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiNuclear factor kB as a target for new drug development in myeloid malignancies.B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.B-cell compartment as the selective target for the treatment of immune thrombocytopenias.Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas.Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes.The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.Low-dose rituximab in adult patients with primary immune thrombocytopenia.The CD47 pathway is deregulated in human immune thrombocytopenia.Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibCombination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency.Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyIncidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia.Molecular response in CML: where is the bar?The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseExpression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage.
P50
Q27851487-6DE96601-7513-41FE-BC53-002EC427B775Q28213621-A978DA74-5FF2-4484-A100-814CA40218AEQ28261333-968AF448-6746-4266-B5AE-6BDE5DD44AE3Q30242015-4724A54C-A9E3-4B1B-B680-9E81A304BAD0Q30245010-DC6B7A26-E99A-4338-A2CD-9C2520858879Q30357011-03C7F750-D188-4D78-9F6F-C4F24EA36AE3Q33292635-84C43CA3-A14F-453C-8AA0-E8A56C15F8A2Q33340979-0077F6DA-2526-421D-BAE6-B0D8B511E48EQ33343973-4DB91909-3D08-41C4-A778-21BA30D9A10EQ33347989-249E1CFF-C2F4-4A95-83D1-56660DBA7F0FQ33357481-92B95D20-4A4E-494B-9AEE-A66C2B4365F6Q33358665-A7B1DF37-6D59-48FF-BE90-70B12BA16A83Q33361455-A99E90D3-978C-4ED4-B0E9-E04D518E4F4CQ33371694-D6D53FF9-FFAD-45E5-B764-85DC68550107Q33376263-0DEADF65-3228-4716-B904-887A18B906D7Q33376304-02ECCBB0-8ABD-4539-8540-DEA5FC6D1846Q33377623-6814FC30-482D-48A5-AE50-41A49E39F619Q33378233-5C997B4C-9425-4CD0-B420-77295D1C1556Q33379235-E13E25A2-BC99-48C7-9967-30638D856B22Q33379777-91360437-8063-49D1-B4A8-24719031E770Q33388109-67F8D247-931F-4C8E-B264-47B760480092Q33390098-F1719E96-AD20-4507-80A5-8C7F92A5AD54Q33390115-94D6D5E1-BFFD-40A8-B20E-964CB1D4582EQ33393546-F58FA4BD-08C0-4033-9B00-D2E9689AE763Q33394812-02B88DE6-D947-4134-A415-2B1A14A37D07Q33396803-394CF264-42E4-4A39-9E06-4DEA68990130Q33398716-43E34851-BB3A-4587-8193-A4FB9927E2B9Q33402505-E94621BD-966E-4ED6-AE39-ED8F7100C8DFQ33403052-8B8A050B-E315-4F00-9B71-B3CCD3AA73E5Q33404090-684E445F-7E9B-4007-9161-946E43EDB47DQ33408546-62B4FDFD-5A64-440F-9C20-345118E18592Q33423072-4D42DC02-BEDC-49E4-844D-88C2251DAA66Q33426475-4E6BE55D-DD2E-4411-B1AD-A2A9A078132BQ33431538-251C0CC9-BD2E-4A12-825D-3C985B22AD20Q33434455-85DC7B84-6C3A-40C8-A622-FFC14739D13BQ33728189-6C457B95-C23F-4E2A-B09E-2ADBEF3A0B79Q33849578-1D03243D-BA7D-4C95-A09D-CED8792C097AQ33948671-CEC763F4-BA73-4126-A7E2-7345E18A61C3Q34032263-8C1591FA-4365-4123-BB2C-DA0A49420A38Q34112282-8D99C87D-B2A7-4444-ABFA-856CA12DC2CF
P50
name
Michele Baccarani
@ast
Michele Baccarani
@en
Michele Baccarani
@nl
type
label
Michele Baccarani
@ast
Michele Baccarani
@en
Michele Baccarani
@nl
prefLabel
Michele Baccarani
@ast
Michele Baccarani
@en
Michele Baccarani
@nl
P1006
P214
P1006
P214
P31
P7859
lccn-n2011187082